Moffitt Cancer Center Researchers Discuss New Frontiers in Breast Cancer Screening

April 04, 2013

TAMPA, Fla. – Researchers at Moffitt Cancer Center predict that advancements in breast cancer screening will need a personalized touch because mammography is not a “one strategy fits all” technology.

Their review “Beyond Mammography: New Frontiers in Breast Cancer Screening” appears in the April 4 issue of The American Journal of Medicine.

“Although mammography remains the gold standard for breast cancer screening, there is increasing awareness that there are subpopulations of women for whom mammography is limited because of its reduced sensitivity based on an individual’s breast density and other factors,” said study lead author Jennifer S. Drukteinis, M.D., assistant member in Moffitt’s Department of Diagnostic Imaging.

The writers refer to a controversial disagreement on mammography screening issues. In 2009, the U.S. Preventive Services Task Force, a panel of health care professionals charged with reviewing published research and making health care policy recommendations, issued guidelines that women should get mammograms every two years starting at age 50. They recommended against screening before 50. Their recommendation generated great controversy, even outrage, because of a well-established convention recommending mammography screening beginning at 40 and, for those with a first-degree relative with breast cancer, screening should start a decade before that relative’s age at diagnosis.

“At present, the task force is the only group or consensus panel in the United States recommending breast cancer screenings to begin at age 50,” said study co-author Blaise P. Mooney, M.D., an assistant member in Moffitt’s Department of Diagnostic Imaging. “There is, however, clear evidence that mammography detects early breast cancers in this population. Data suggest that large-scale screening reduces mortality.”

As effective as mammography has been, the authors consider it an imperfect screening tool.

The sensitivity of mammography is highly variable, the authors point out. The effectiveness for women with fatty breast tissue is as high as 98 percent while the effectiveness for women with dense breasts can be as low as 36 percent. Women who undergo annual mammography may still present with cancers found only on physical examination, they said. Additionally, some studies suggest that radiation exposure may contribute to an increase in breast cancer incidence in high-risk populations.

More successful breast cancer screening requires increased sensitivity and specificity while limiting costs and radiation burden, the authors recommended.

They also suggested that optimal patient care will require a new screening paradigm with patient-specific strategies tailored to risk based on family history, age, genetic profiles and breast density.

“The sensitivity of mammography is inversely proportional to breast density,” explained Mooney. “Owing to decreased sensitivity in women with dense breast tissue, but with attention to radiation concerns and a high rate of false positives, breast imagers are adapting with new technologies.”

According to the authors, those new technologies include low-dose mammography, contrast-enhanced mammography (evaluates blood flow in the breast), automated whole breast ultrasound, molecular imaging, MRI and tomosynthesis (multiple mammographic “slices” through the breast, similar to a CT scan).

“Decreases in mortality have not been proved with any of these emerging technologies,” Drukteinis said. “Once more, it is unlikely that any of these new technologies will replace mammography. The role of these new technologies is primarily as an adjunct to screening mammography and can be used in a combination tailored to the individual’s risk factors and breast density, with the goal of maximizing sensitivity and specificity.”

“Given the heterogeneity of the human population, a perfect imaging technology for breast cancer screening will likely never be found. In fact, because of this heterogeneity, the very concept of one strategy fits all may be outmoded,” Drukteinis said.

The authors agree that new technologies will be increasingly personalized, integrating patient-specific and age-dependent factors of cancer risk “with selective application of specific screening technologies best suited to the woman’s age, risk and breast density.”

About Moffitt Cancer Center

Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Since 1999, Moffitt has been listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. With more than 4,200 employees, Moffitt has an economic impact on the state of nearly $2 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on Facebook, twitter and YouTube.

Media release by Florida Science Communications

###